These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 32993261)

  • 1. [The change in nutritional status of pancreatic cancer patients undergoing neoadjuvant therapy and its influence on these patients' postoperative outcomes as well as prognosis].
    Yu ZP; Chen W; Dai MH
    Zhonghua Wai Ke Za Zhi; 2020 Oct; 58(10):754-757. PubMed ID: 32993261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival.
    Rose JB; Rocha FG; Alseidi A; Biehl T; Moonka R; Ryan JA; Lin B; Picozzi V; Helton S
    Ann Surg Oncol; 2014 May; 21(5):1530-7. PubMed ID: 24473642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Borderline resectable pancreatic cancer and the role of neoadjuvant chemoradiotherapy.
    di Sebastiano P; Grottola T; di Mola FF
    Updates Surg; 2016 Sep; 68(3):235-239. PubMed ID: 27629483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low lymphocyte monocyte ratio after neoadjuvant therapy predicts poor survival after pancreatectomy in patients with borderline resectable pancreatic cancer.
    Kawai M; Hirono S; Okada KI; Miyazawa M; Shimizu A; Kitahata Y; Kobayashi R; Ueno M; Hayami S; Tanioka K; Yamaue H
    Surgery; 2019 Jun; 165(6):1151-1160. PubMed ID: 30765142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant Therapy of Pancreatic Cancer: Definitions and Benefits.
    Heinrich S; Lang H
    Int J Mol Sci; 2017 Jul; 18(8):. PubMed ID: 28933761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Controversial issues of neoadjuvant treatment in borderline resectable pancreatic cancer.
    Kang CM; Hwang HK; Choi SH; Lee WJ
    Surg Oncol; 2013 Jun; 22(2):123-31. PubMed ID: 23518243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of the prognostic nutritional index in esophageal cancer patients undergoing neoadjuvant chemotherapy.
    Nakatani M; Migita K; Matsumoto S; Wakatsuki K; Ito M; Nakade H; Kunishige T; Kitano M; Kanehiro H
    Dis Esophagus; 2017 Aug; 30(8):1-7. PubMed ID: 28575242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant Chemotherapy Enhances Local Postoperative Histopathological Tumour Stage in Borderline Resectable Pancreatic Cancer - A Matched-Pair Analysis.
    Timmermann L; Rosumeck N; Klein F; Pratschke J; Pelzer U; Bahra M; Malinka T
    Anticancer Res; 2019 Oct; 39(10):5781-5787. PubMed ID: 31570482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Characteristics of Patients Experiencing Pathologic Complete Response Following Neoadjuvant Therapy for Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma.
    Hashemi-Sadraei N; Gbolahan OB; Salfity H; O'Neil B; House MG; Shahda S
    Am J Clin Oncol; 2018 Oct; 41(10):982-985. PubMed ID: 28968257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgery.
    Barnes CA; Chavez MI; Tsai S; Aldakkak M; George B; Ritch PS; Dua K; Clarke CN; Tolat P; Hagen C; Hall WA; Erickson BA; Evans DB; Christians KK
    Surgery; 2019 Sep; 166(3):277-285. PubMed ID: 31272811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nutritional optimization during neoadjuvant therapy prior to surgical resection of esophageal cancer-a narrative review.
    Huddy JR; Huddy FMS; Markar SR; Tucker O
    Dis Esophagus; 2018 Jan; 31(1):1-11. PubMed ID: 29024949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy.
    Barugola G; Partelli S; Crippa S; Capelli P; D'Onofrio M; Pederzoli P; Falconi M
    Am J Surg; 2012 Feb; 203(2):132-9. PubMed ID: 21824596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette study.
    Heinrich S; Besselink M; Moehler M; van Laethem JL; Ducreux M; Grimminger P; Mittler J; Lang H; Lutz MP; Lesurtel M;
    BMC Cancer; 2019 Jul; 19(1):675. PubMed ID: 31288786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunonutrition and prehabilitation in pancreatic cancer surgery: A new concept in the era of ERAS® and neoadjuvant treatment.
    De Luca R; Gianotti L; Pedrazzoli P; Brunetti O; Rizzo A; Sandini M; Paiella S; Pecorelli N; Pugliese L; Pietrabissa A; Zerbi A; Salvia R; Boggi U; Casirati A; Falconi M; Caccialanza R
    Eur J Surg Oncol; 2023 Mar; 49(3):542-549. PubMed ID: 36577556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Current consensus and controversy in neoadjuvant therapy for pancreatic cancer].
    Ou ZL; Li YX; Ji LD; Ke MJ
    Zhonghua Wai Ke Za Zhi; 2020 Feb; 58(2):99-104. PubMed ID: 32074807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis.
    Choi JG; Nipp RD; Tramontano A; Ali A; Zhan T; Pandharipande P; Dowling EC; Ferrone CR; Hong TS; Schrag D; Fernandez-Del Castillo C; Ryan DP; Kong CY; Hur C
    Oncologist; 2019 Jul; 24(7):945-954. PubMed ID: 30559125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant therapy for non-metastatic pancreatic ductal adenocarcinoma.
    Winner M; Goff SL; Chabot JA
    Semin Oncol; 2015 Feb; 42(1):86-97. PubMed ID: 25726054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcome following neoadjuvant therapy for resectable and borderline resectable pancreatic cancer compared to upfront surgery: a meta-analysis of comparative studies by intention-to-treat analysis.
    Unno M; Hata T; Motoi F
    Surg Today; 2019 Apr; 49(4):295-299. PubMed ID: 30877550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Impact of Neoadjuvant Therapy on Nutritional Status in Pancreatic Cancer.
    Tashiro M; Yamada S; Sonohara F; Takami H; Suenaga M; Hayashi M; Niwa Y; Tanaka C; Kobayashi D; Nakayama G; Koike M; Fujiwara M; Fujii T; Kodera Y
    Ann Surg Oncol; 2018 Oct; 25(11):3365-3371. PubMed ID: 30097739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of preoperative anti-cancer therapy on resectability and perioperative outcomes in patients with pancreatic cancer: project study by the Japanese Society of Hepato-Biliary-Pancreatic Surgery.
    Motoi F; Unno M; Takahashi H; Okada T; Wada K; Sho M; Nagano H; Matsumoto I; Satoi S; Murakami Y; Kishiwada M; Honda G; Kinoshita H; Baba H; Hishinuma S; Kitago M; Tajima H; Shinchi H; Takamori H; Kosuge T; Yamaue H; Takada T
    J Hepatobiliary Pancreat Sci; 2014 Feb; 21(2):148-58. PubMed ID: 23913634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.